VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 25, 2016) - Cannabix Technologies Inc. (CSE:BLO)(OTC PINK:BLOZF) (the "Company") provides an update on the Company's efforts on development of its FAIMS (high-field asymmetric waveform ion mobility spectrometry) Cannabix Marijuana Breathalyzer based instrument for detection of trace amounts of Tetrahydrocannabinol ("THC"). The Company is pleased to report that it has developed a stand-alone desktop sized "Beta 1.0" device with a proprietary configurable high voltage power supply which operates on conventional power sources. Preliminary lab tests of the FAIMS device coupled with conventional quadrupole mass spectrometry have shown similar levels of detection for THC standards. 

The FAIMS cell employed in this device is 4X smaller than the prior benchtop version and has a 10X reduction in power supply requirements, which allows a drastically smaller footprint. The current power supply is readily configurable for ongoing testing and is designed to integrate with the non-radioactive ionization source and soon to be implemented customized detector. The Company expects to complete a "Beta 2.0" device that will be prepared for external testing. With ongoing technical advances, the company is rapidly reducing the size of each internal component and is improving the engineering of the electronics. 

Dr. Raj Attariwala commented, "This version of the smaller FAIMS cell and its critical reduction in power supply requirements with maintained THC sensitivity is a key step forward in preparing for field testing."

Kal Malhi, President, commented, "Cannabix is moving quickly towards launching our FAIMS based Cannabix Marijuana Breathalyzer and completing external testing. With up to nine states in the US voting on marijuana legalization measures this fall, the need for a marijuana breathalyzer is becoming ever critical and we believe our timing for external testing of the Cannabix Marijuana Breathalyzer will coincide with further states legalizing marijuana."

For more information visit cannabixtechnologies.com

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. This technology would be used to provide detection of use of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. In particular, Cannabix is focused on developing breath testing devices for THC detection that would target recent use of THC, in contrast to saliva or urine testing for THC which can be invasive and take considerable time for laboratory analysis. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous. 

We seek Safe Harbor.

On behalf of the Board of Directors

Rav Mlait
CEO
Cannabix Technologies Inc.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.